Developer docs
API playgroundTry for free, no card

Search company profiles

Psylink

Full company profile

uuid0002w32

Namestring
Psylink
Websiteurl
psylink.io
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Psylink is a Vilnius, Lithuania-based biotechnology company founded in 2020 that develops a yeast-cell biosynthesis platform for small-molecule psychedelic drug production. The company's core technology genetically modifies yeast cells to reconstruct the naturally occurring biosynthetic pathways of target molecules — including tryptamines (psilocybin, DMT, 5-MeO-DMT), ergolines (LSD), and phenethylamines (mescaline) — and is being extended to new molecular entities beyond naturally occurring compounds. A pending patent application (filed 2022-2023) covers the platform, and Psylink obtained a Schedule I substance license in 2021, enabling controlled-substance R&D in a GMP-compatible fermentation framework.

The company operates a B2B model targeting two primary segments: research institutions studying psychedelics for therapeutic applications, and pharmaceutical companies requiring GMP-compatible, scalable manufacturing of psychedelic drug substances for clinical trials. Psylink is pre-revenue, with stated revenue intent around licensing, contract manufacturing, or partnership deals with pharma companies. Distribution runs through direct enterprise engagement rather than traditional channels, supported by a minimal digital footprint (company website plus Instagram, LinkedIn, and Twitter profiles).

Psylink has raised approximately $729,303 in cumulative disclosed funding across a 2023 round led by FIRSTPICK and a 2025 round led by Coinvest Capital with BSV Ventures and FIRSTPICK participating. The company remains small (1-10 employees), founder-controlled, and at an early R&D and clinical-supply stage with no disclosed commercial customers, contracts, or product revenue.

Short descriptiontext

Psylink is a Lithuanian biotech that uses genetically modified yeast cells to biosynthesize psychedelic compounds — including psilocybin, DMT, LSD, and mescaline — for clinical research institutions and pharmaceutical companies pursuing psychedelic therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVilnius, Lithuania
HQ citystring
Vilnius
HQ countrystring
Lithuania
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
psychedelic biosynthesis, yeast-based drug development, GMP contract manufacturing, small-molecule therapeutics, novel molecular entities
Industry3 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1B2B Drug Development Services
TypeLicensing Royalties
Description

Pre-revenue biotech company developing biosynthesis platform for pharmaceutical applications. Revenue model likely based on licensing, contract manufacturing, or partnership deals with pharmaceutical companies for drug development.

psylink.io
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Psylink develops and operates a proprietary yeast-based biosynthesis platform for the sustainable, scalable, and cost-effective production of psychedelic and other small-molecule drug substances. The company genetically modifies yeast cells to recreate biosynthetic pathways for naturally occurring molecules such as psilocybin, DMT, LSD, and mescaline, while also producing novel next-generation molecular entities. Outputs are intended for pharmaceutical companies and research institutions requiring GMP-compatible drug substances for clinical research and therapeutic development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Psylink is a biotechnology company offering a single unified biosynthesis platform for small-molecule drug development, with two complementary product lines: Classic Psychedelic Compounds (Tryptamines including Psilocybin and DMT, Ergolines including LSD, and Phenethylamines including Mescaline) produced via yeast-based biosynthesis, and New Molecular Entities representing next-generation novel compounds. The platform uses genetic modification of yeast cells to recreate naturally occurring biosynthetic pathways, providing sustainable, scalable, and GMP-compatible production of drug products for clinical research.

Product and service2 records
1Yeast-Based Biosynthesis Platform
CategoryBiopharmaceutical Manufacturing Platform
Description

Proprietary yeast-based biosynthesis platform using genetically modified yeast cells to recreate naturally occurring biosynthetic pathways for producing psychedelic and other small-molecule drug substances. Serves pharmaceutical companies and academic research institutions needing GMP-compatible drug substances for clinical research and therapeutic development.

2Classic Psychedelic Compounds
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Research Institutions
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with research institutions for novel indications (2023-2024) and manufacturing of additional drug products for clinical research. No specific institution names provided in source material.

psylink.io
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage DMT-assisted therapy developer (SPL026) acquired by atai in 2024. A peer to Psylink's targeted tryptamine work and another potential API customer.

TypeBroad incumbent
Description

Irish clinical-stage company developing 5-MeO-DMT (GH001) for treatment-resistant depression. Direct overlap with Psylink's tryptamine platform and a potential supply/licensing counterparty.

3atai Life Sciences
TypeBroad incumbent
Description

Berlin-based mental health biotech platform holding multiple psychedelic drug developers (including psilocybin DMT programs). Potential customer for Psylink's API manufacturing and a benchmark for psychedelic biotech valuations.

TypeBroad incumbent
Description

Established industrial biotechnology company operating yeast fermentation platforms for ingredient manufacturing at scale. Comparable technology stack (engineered yeast strains, fermentation scale-up) though in different end markets (cosmetics, flavors) than Psylink.

TypeBroad incumbent
Description

Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analog (CYB003). Comparable buyer/customer archetype for Psylink's psilocybin and next-gen tryptamine manufacturing capabilities.

TypeEmerging player
Description

Drug development and extraction company focused on naturally-derived psychedelic APIs. Comparable business model targeting GMP psychedelic drug substance manufacturing, though via plant extraction rather than biosynthesis.

TypeDirect peer
Description

Danish synthetic biology company engineering yeast for biosynthesis of cannabinoid and psychedelic compounds. Closest direct competitor to Psylink in yeast-based psychedelic API production with GMP ambitions.

TypeDirect peer
Description

Montreal-based biotech using yeast fermentation to biosynthesize cannabinoids and other compounds including psilocybin. Directly comparable to Psylink as a yeast-based biosynthesis platform for psychoactive small molecules targeting pharmaceutical applications.

TypeBroad incumbent
Description

Clinical-stage psychedelic mental health company developing psilocybin therapy (COMP360). A potential customer of Psylink's manufacturing rather than a direct platform competitor, but the leading demand-side reference point for GMP psilocybin supply.

10Psylo (formerly EmpathBio)
TypeEmerging player
Description

Australian-based designer of novel psychedelic compounds with proprietary tryptamine analogs. Comparable emerging player in next-generation psychedelic drug development where Psylink's NME platform could be a manufacturing partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Psylink

Biopharmaceutical Manufacturingpsylink.io

Psylink is a Lithuanian biotech that uses genetically modified yeast cells to biosynthesize psychedelic compounds — including psilocybin, DMT, LSD, and mescaline — for clinical research institutions and pharmaceutical companies pursuing psychedelic therapeutics.

What Psylink does

Psylink is a Vilnius, Lithuania-based biotechnology company founded in 2020 that develops a yeast-cell biosynthesis platform for small-molecule psychedelic drug production. The company's core technology genetically modifies yeast cells to reconstruct the naturally occurring biosynthetic pathways of target molecules — including tryptamines (psilocybin, DMT, 5-MeO-DMT), ergolines (LSD), and phenethylamines (mescaline) — and is being extended to new molecular entities beyond naturally occurring compounds. A pending patent application (filed 2022-2023) covers the platform, and Psylink obtained a Schedule I substance license in 2021, enabling controlled-substance R&D in a GMP-compatible fermentation framework.

The company operates a B2B model targeting two primary segments: research institutions studying psychedelics for therapeutic applications, and pharmaceutical companies requiring GMP-compatible, scalable manufacturing of psychedelic drug substances for clinical trials. Psylink is pre-revenue, with stated revenue intent around licensing, contract manufacturing, or partnership deals with pharma companies. Distribution runs through direct enterprise engagement rather than traditional channels, supported by a minimal digital footprint (company website plus Instagram, LinkedIn, and Twitter profiles).

Psylink has raised approximately $729,303 in cumulative disclosed funding across a 2023 round led by FIRSTPICK and a 2025 round led by Coinvest Capital with BSV Ventures and FIRSTPICK participating. The company remains small (1-10 employees), founder-controlled, and at an early R&D and clinical-supply stage with no disclosed commercial customers, contracts, or product revenue.

Psylink firmographics

Firmographics
Name
Psylink
Website
https://psylink.io
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Psylink is a Lithuanian biotech that uses genetically modified yeast cells to biosynthesize psychedelic compounds — including psilocybin, DMT, LSD, and mescaline — for clinical research institutions and pharmaceutical companies pursuing psychedelic therapeutics.
Ownership category
akta.pro rank

Psylink industry classification

Industry
Product category
Biopharmaceutical Manufacturing
NAICS
Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Psychedelic biosynthesis
  • Yeast-based drug development
  • GMP contract manufacturing
  • Small-molecule therapeutics
  • Novel molecular entities

Where Psylink is headquartered

Location

Headquarters

HQ city
Vilnius
HQ country
Lithuania
HQ region
Europe

Markets served

Psylink business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. B2B Drug Development Services: Pre-revenue biotech company developing biosynthesis platform for pharmaceutical applications. Revenue model likely based on licensing, contract manufacturing, or partnership deals with pharmaceutical companies for drug development.

Go-to-market motion1 record

Marketing channels4 records

Psylink product offering

Product offering

Core offering

Psylink develops and operates a proprietary yeast-based biosynthesis platform for the sustainable, scalable, and cost-effective production of psychedelic and other small-molecule drug substances. The company genetically modifies yeast cells to recreate biosynthetic pathways for naturally occurring molecules such as psilocybin, DMT, LSD, and mescaline, while also producing novel next-generation molecular entities. Outputs are intended for pharmaceutical companies and research institutions requiring GMP-compatible drug substances for clinical research and therapeutic development.

Product overview

Psylink is a biotechnology company offering a single unified biosynthesis platform for small-molecule drug development, with two complementary product lines: Classic Psychedelic Compounds (Tryptamines including Psilocybin and DMT, Ergolines including LSD, and Phenethylamines including Mescaline) produced via yeast-based biosynthesis, and New Molecular Entities representing next-generation novel compounds. The platform uses genetic modification of yeast cells to recreate naturally occurring biosynthetic pathways, providing sustainable, scalable, and GMP-compatible production of drug products for clinical research.

Differentiator

Problem solved

Functional benefit

Products and services

  • Yeast-Based Biosynthesis Platform Proprietary yeast-based biosynthesis platform using genetically modified yeast cells to recreate naturally occurring biosynthetic pathways for producing psychedelic and other small-molecule drug substances. Serves pharmaceutical companies and academic research institutions needing GMP-compatible drug substances for clinical research and therapeutic development.
  • Classic Psychedelic Compounds

Companies that use Psylink

Customer profile

Segments2 records

Ideal customer profiles2 records

Psylink technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Psylink partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Research InstitutionscoreStrategic or Co-development PartnerCollaboration with research institutions for novel indications (2023-2024) and manufacturing of additional drug products for clinical research. No specific institution names provided in source material.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Psylink competitors and assessment

Company assessment

Emerging players

  • Small Pharma: Clinical-stage DMT-assisted therapy developer (SPL026) acquired by atai in 2024. A peer to Psylink's targeted tryptamine work and another potential API customer.
  • Filament Health: Drug development and extraction company focused on naturally-derived psychedelic APIs. Comparable business model targeting GMP psychedelic drug substance manufacturing, though via plant extraction rather than biosynthesis.
  • Psylo (formerly EmpathBio): Australian-based designer of novel psychedelic compounds with proprietary tryptamine analogs. Comparable emerging player in next-generation psychedelic drug development where Psylink's NME platform could be a manufacturing partner.

Broad incumbents

  • GH Research: Irish clinical-stage company developing 5-MeO-DMT (GH001) for treatment-resistant depression. Direct overlap with Psylink's tryptamine platform and a potential supply/licensing counterparty.
  • atai Life Sciences: Berlin-based mental health biotech platform holding multiple psychedelic drug developers (including psilocybin DMT programs). Potential customer for Psylink's API manufacturing and a benchmark for psychedelic biotech valuations.
  • Amyris: Established industrial biotechnology company operating yeast fermentation platforms for ingredient manufacturing at scale. Comparable technology stack (engineered yeast strains, fermentation scale-up) though in different end markets (cosmetics, flavors) than Psylink.
  • Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analog (CYB003). Comparable buyer/customer archetype for Psylink's psilocybin and next-gen tryptamine manufacturing capabilities.
  • Compass Pathways: Clinical-stage psychedelic mental health company developing psilocybin therapy (COMP360). A potential customer of Psylink's manufacturing rather than a direct platform competitor, but the leading demand-side reference point for GMP psilocybin supply.

Direct peers

  • Octarine Bio: Danish synthetic biology company engineering yeast for biosynthesis of cannabinoid and psychedelic compounds. Closest direct competitor to Psylink in yeast-based psychedelic API production with GMP ambitions.
  • Hyasynth Biologicals: Montreal-based biotech using yeast fermentation to biosynthesize cannabinoids and other compounds including psilocybin. Directly comparable to Psylink as a yeast-based biosynthesis platform for psychoactive small molecules targeting pharmaceutical applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Psylink social profiles

Digital presence

Psylink financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Psylink leadership team

Management profile

Number of profiles

Profiles6 records

Psylink funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Psylink M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psylink

What does Psylink do?

Psylink develops and operates a proprietary yeast-based biosynthesis platform for the sustainable, scalable, and cost-effective production of psychedelic and other small-molecule drug substances. The company genetically modifies yeast cells to recreate biosynthetic pathways for naturally occurring molecules such as psilocybin, DMT, LSD, and mescaline, while also producing novel next-generation molecular entities. Outputs are intended for pharmaceutical companies and research institutions requiring GMP-compatible drug substances for clinical research and therapeutic development.

Is Psylink a public or private company?

Psylink is a private company. It is classified as venture growth investor backed and is currently operating.

When was Psylink founded?

Psylink was founded in 2020. It employs 1 to 10 people.

Where is Psylink based?

Psylink is headquartered in Vilnius, Lithuania, in the Europe region.

How does Psylink make money?

One revenue line is on record: B2B Drug Development Services.

Who are Psylink's main competitors?

Emerging players on record are Small Pharma, Filament Health and Psylo (formerly EmpathBio). Broad incumbents are GH Research, atai Life Sciences, Amyris, Cybin and Compass Pathways. Direct peers are Octarine Bio and Hyasynth Biologicals.

Does Psylink have an API?

No public API is recorded for Psylink.

What industry is Psylink in?

Psylink's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech.euCoinvest Capital backs Psylink’s next-gen mental health biotech solutionLithuanian startup Psylink raised €501,521 in a pre-seed round led by Coinvest Capital to advance its biotech platform for plant- and fungi-derived mental health compounds. The funding will support discovery of novel compounds for depression and PTSD, targeting patients unresponsive to conventional treatments.BebeezPsylink secures €501K pre-seed – BeBeez InternationalVilnius-based biotech Psylink raised €501,521 in pre-seed funding led by Coinvest Capital, with participation from Firstpick, BSV Ventures, and angel investors. The funds will support its engineered yeast platform for producing plant- and fungi-derived compounds for mental health therapies, targeting depression and PTSD.BebeezLithuanian BioTech platform Psylink raises over €500k for mental health innovation – BeBeez InternationalPsylink, a Vilnius-based biotech startup, raised over €500k in a pre-Seed round led by Coinvest Capital. The funds will advance its platform for producing fungi-derived compounds and screening novel candidates for depression and PTSD. The company targets patients who do not respond to conventional treatments.AinPsylink raises €501K to develop innovative treatments for mental healtPsylink, a Lithuanian biotech, raised €501,521 in a pre-seed round led by Coinvest Capita, with Firstpick, BSV, and angel investors. The funds will advance its platform for sustainable plant- and fungi-derived compounds and accelerate screening of novel molecular candidates for preclinical validation.SynBioBetaEnabling Psychedelics Research with Precision FermentationPsylink and CB Therapeutics are utilizing precision fermentation to produce psychedelics like psilocybin in engineered yeast, aiming to overcome the low yields and sustainability issues associated with mushroom extraction. This synthetic biology approach enables consistent quality, scalable production, and the development of patentable psychedelic derivatives for treating mental health disorders.